The European Medicines Agency has launched a public consultation on its future guideline for the evaluation of methods to measure genetic-based responses to drugs.
The agency has released a paper on how these methods can be used to evaluate drugs, and in particular how genetic variability should be considered systematically when monitoring the safety of medicines.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.